BridgeBio Pharma, Inc. (BBIO)
81.05
-0.45
(-0.55%)
USD |
NASDAQ |
Aug 24, 16:00
80.04
-1.01
(-1.25%)
After-Hours: 20:00
BridgeBio Pharma Profit Margin (Quarterly) : -63.97% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -63.97% |
| March 31, 2026 | -85.63% |
| December 31, 2025 | -126.2% |
| September 30, 2025 | -153.2% |
| June 30, 2025 | -166.2% |
| March 31, 2025 | -145.4% |
| December 31, 2024 | -4.55K% |
| September 30, 2024 | -6.01K% |
| June 30, 2024 | -3.48K% |
| March 31, 2024 | -17.13% |
| December 31, 2023 | -9.76K% |
| September 30, 2023 | -4.39K% |
| June 30, 2023 | -9.79K% |
| March 31, 2023 | -7.82K% |
| Date | Value |
|---|---|
| December 31, 2022 | -7.52K% |
| September 30, 2022 | -41.48K% |
| June 30, 2022 | -3.47% |
| March 31, 2022 | -11.88K% |
| December 31, 2021 | -1.18K% |
| September 30, 2021 | -6.87K% |
| June 30, 2021 | -188.9% |
| March 31, 2021 | -37.03K% |
| December 31, 2020 | -110.7K% |
| September 30, 2020 | -1.60K% |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | -609.0% |
| September 30, 2019 | -226.9% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 12.74% |
| Ionis Pharmaceuticals, Inc. | -42.79% |
| Pfizer Inc. | -1.64% |
| Vertex Pharmaceuticals, Inc. | 32.89% |
| BioMarin Pharmaceutical, Inc. | 4.49% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -62.65% |
| Return on Invested Capital | -80.78% |
| Gross Profit Margin (Quarterly) | 93.68% |
| Operating Margin (Quarterly) | -43.94% |
| Return on Net Operating Assets | -299.8% |